Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3097 - Detection of early cardiac effects of Docetaxel Plus Trastuzumab and Pertuzumab through strain rate imaging in Patients with HER2-Positive Metastatic Breast Cancer


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Supportive Care and Symptom Management;  Staging Procedures (not Imaging);  Breast Cancer


Vasiliki Michalaki


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


V. Michalaki1, G. Koutroulis1, I. Psychogios1, E. Karvouni2, I. Vasiliou1, C. Papadimitriou1

Author affiliations

  • 1 2nd Department Of Surgery, Areteion Hospital, University of Athens, 11528 - Athens/GR
  • 2 Histopathology Department, Areteion Hospital, University of Athens, 11528 - Athens/GR


Abstract 3097


Dual anti- HER2 therapy with trastuzumab and pertuzumab in combination with taxane-based chemotherapy improves overall survival in patients with metastatic HER2-positive breast cancer. There is a critical need to investigate the potential cardiotoxicity of dual anti-HER2 blockade, given the importance of HER2 signaling in cardiac homeostasis and stress response. Sequential left ventricular (LV) ejection fraction (EF) assessment has been mandated to detect myocardial dysfunction. Changes in cardiac function induced by this therapy, however, are subtle and difficult to quantitate by conventional imaging methods. Doppler myocardial imaging-based velocity, strain, and strain rate measurements have been shown to sensitively quantify abnormalities in cardiac function in other settings. The aim of this study was to determine if sensitive indices of left ventricular (LV) dysfunction, specifically strain rate imaging, would be useful for addressing the early detection of dual anti-HER2 mediated cardiotoxicity.


Patients with 0-1 lines of prior therapy were treated with 8 cycles of docetaxel (75mg/m(2) plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks. Conventional and Doppler myocardial imaging echocardiography were obtained at baseline and every 2 cycles of treatment. Segmental peak systolic longitudinal and radial velocity, strain, and strain rate (SR) were measured.


Twenty-seven women (median age 52.2 years) were enrolled in the study. There was no overall change in Left ventricular dimensions, ejection fraction, and systolic myocardial velocity. In contrast, a significant reduction in longitudinal and radial strain and strain rate was found after 8 cycles (longitudinal strain -12.8% +/- 2.2% vs baseline (P = .001); radial strain 29.3% +/- 7.1% vs 50.3% +/- 10.6%, P < .001 vs baseline). Changes in radial function appeared earlier and were more pronounced than in longitudinal direction.


In contrast with conventional echocardiography myocardial velocity measurements allowed detecting subtle changes in longitudinal and radial left ventricular function after 8 cycles of therapy. We suggest that strain rate imaging identifies preclinical myocardial dysfunction earlier than conventional measures in women undergoing treatment with dual anti-HER2 therapy for metastatic breast cancer and could be used for cardiac function monitoring.

Clinical trial identification

Legal entity responsible for the study

Vasiliki Michalaki




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.